Eskayef_Bangladesh_Limited

Eskayef Pharmaceuticals Ltd.

Eskayef Pharmaceuticals Ltd.

Bangladeshi pharmaceutical company

Eskayef Pharmaceuticals Ltd., also known as SK+F, is a pharmaceutical company in Bangladesh. It belongs to the Transcom Group.[1][2] Simeen Rahman is the Managing Director and CEO of the company.[2][3]

Quick Facts Company type, Industry ...

History

Eskayef Bangladesh Ltd., a successor of Smith, Kline & French in Bangladesh, was acquired by Transcom in 1990.[2] According to an IMS report, the company was among the top six pharmaceutical companies operating in Bangladesh in terms of sales in 2021.[4] By 2021, it exported finished products to 65 countries.[2] The company was renamed Eskayef Pharmaceuticals Limited in January 2017.[5]

Products

The company is engaged in the manufacture and marketing of a wide range of therapeutic drugs, bulk pellets and animal health and nutrition products[6] including the oral anti covid medication Molnupiravir[7] & Nirmatrelvir co-packaged with Ritonavir and injectable Remdesivir.

References

  1. [1]
    Iqbal, Farah K. (2016-09-19). "What makes the market tick?". Dhaka Tribune (Op-ed). Retrieved 2016-10-03.
  2. [2]
    "Eskayef sales jump manifold". The Daily Star. 2015-12-29. Retrieved 2016-10-03.
  3. [3]
    "'I am the brand'". Prothom Alo. Archived from the original on 2016-09-24. Retrieved 2016-10-03.
  4. [4]
    Akter, Sayeda (2009-08-23). "Pharma industry set for expansion". The Daily Star. Retrieved 2016-10-03.
  5. [5]
    "Eskayef pledges to conquer odds with courage". The Daily Star. 2017-01-24.
  6. [6]
    "Eskayef beats rivals in sales growth". The Daily Star. 2012-01-26.
  7. [7]
    "Beximco, Eskayef to produce Covid drug". businesspostbd.com. Retrieved 2021-11-10.

Further reading


Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Eskayef_Bangladesh_Limited, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.